Last updated: 6 October 2021 at 7:43pm EST

Hilde Steineger Net Worth



Hilde Steineger biography

Dr. Hilde H. Steineger Ph.D. serves as Independent Director of the Company. Dr. Steineger is a board member of Nordic Nanovector ASA. Dr. Steineger previously served as Head of Strategic Innovation Management in Nutrition & Health Division of BASF, and as Head of Global Omega-3 Innovation Management at Pronova BioPharma ASA, a BASF company, from April 2013 to May 2015. From August 2007 to June 2010, Dr. Steineger was Head of Investor Relations for Pronova BioPharma and Vice President Business Development in Pronova BioPharma from November 2009 to April 2013. She previously served as a member of the board of directors of PCI Biotech AS, Afiew AS, Algeta ASA, Weifa AS, Inven2 AS, Alertis AS, Clavis Pharma ASA and Biotech Pharmacon ASA. Dr. Steineger holds a Ph.D. in medical biochemistry from University of Oslo and an MSc in molecular biology/biotechnology.

What is the salary of Hilde Steineger?

As the Independent Director of Strongbridge Biopharma plc, the total compensation of Hilde Steineger at Strongbridge Biopharma plc is 173,317$. There are 6 executives at Strongbridge Biopharma plc getting paid more, with Frederic Cohen having the highest compensation of 1,093,830$.



How old is Hilde Steineger?

Hilde Steineger is 54, he's been the Independent Director of Strongbridge Biopharma plc since 2014. There are 5 older and 3 younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.

What's Hilde Steineger's mailing address?

Hilde's mailing address filed with the SEC is 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PA, 19053.

Insiders trading at Strongbridge Biopharma plc

Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over 0$ worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth 8,846,818$ . The most active insiders traders include Associates, L.L.C.Caxton Co...Garheng KongJeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of 593,478$. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth 17,040$.



What does Strongbridge Biopharma plc do?

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.



What does Strongbridge Biopharma plc's logo look like?

Strongbridge Biopharma plc logo

Strongbridge Biopharma plc executives and stock owners

Strongbridge Biopharma plc executives and other stock owners filed with the SEC include: